First-Line Chemotherapy of Disseminated Germ Cell Tumors

Hematology/Oncology Clinics of North America

Volumn 25, Issue 3, 2011, Pages 543-556

  Nichols, Craig ^a   Kollmannsberger, Christian ^b  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Chemotherapy; Cisplatin; Germ cell; Testicular cancer

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; VINBLASTINE;

CANCER CHEMOTHERAPY; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HUMAN; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; GERMINOMA; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 79955827623     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.03.011     Document Type: Review

References (37)

1. Rosenberg B., van Camp L., Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205:698-699.
2. Lippman A., Helson C., Helson L., et al. Clinical trials of cis- diamminedichloroplatinum (NSC-119875). Cancer Treat Rep 1973, 57:191-200.
3. Einhorn L., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977, 87:293-298.
4. Einhorn L.H., Williams S.D. Chemotherapy of disseminated testicular cancer. Cancer 1980, 46:1339-1344.
5. Einhorn L.H., Williams S.D., Troner M., et al. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981, 305:727-731.
6. Williams S.D., Einhorn L.H., Greco F.A., et al. VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer 1980, 46:2154-2158.
7. Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987, 316(23):1435-1440.
8. Birch R., Williams S., Cone A., et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986, 4:786-792.
9. Bosl G.J., Geller N.L., Cirnncione C., et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983, 43:3403-3407.
10. International Germ-Cell Cancer Collaborative Group. International Germ-Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ-cell cancers. J Clin Oncol 1997, 15:594-603.
11. Einhorn L.H., Williams S.D., Loehrer P.J., et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989, 7:387-391.
12. Saxman S.B., Finch D., Gonin R., et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience. J Clin Oncol 1998, 16:702-706.
13. Loehrer P.J., Johnson D., Elson P., et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995, 13:470-476.
14. Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993, 11(4):598-606.
15. Horwich A., Sleijfer D.T., Fosså S.D., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997, 15(5):1844-1852.
16. Bokemeyer C., Köhrmann O., Tischler J., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996, 7(10):1015-1021.
17. Grimison P., Stockler M., Thomson D., et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst 2010, 102:1253-1262.
18. deWit R., Stoter G., Kaye S.B., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group. J Clin Oncol 1997, 15:1837-1843.
19. Culine S., Kerbrat P., Kramar A., et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007, 18:917-924.
20. Nichols C., Williams S., Loehrer P., et al. Randomized study of cisplatin dose intensity in advanced germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991, 9:1163-1172.
21. Nichols C.R., Catalano P.J., Crawford E.D., et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998, 16:1287-1293.
22. Hinton S., Catalano P.J., Einhorn L.H., et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003, 97(8):1869-1875.
23. Wheeler B.M., Loehrer P.J., Williams S.D., et al. Ifosfamide in refractory male germ cell tumors. J Clin Oncol 1986, 4:28-34.
24. Motzer R.J., Nichols C.R., Margolin K.A., et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007, 25:247-256.
25. Culine S., Kramar A., Théodore C., et al. randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008, 26(3):421-427.
26. Kaye S.B., Mead G.M., Fossa S., et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998, 16:692-701.
27. Christian J.A., Huddart R.A., Norman A., et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003, 21(5):871-877.
28. Grimison P.S., Thomson D.B., Stockler M., et al. Accelerated BEP for advanced germ cell tumors: an ongoing multicenter phase I/II trial. American Society of Clinical Oncology Genitourinary Cancers Symposium 2010, [abstract: 258].
29. Olofsson S., Dahl O., Jerkeman M., et al. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): a report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J Clin Oncol 2009, 27(Suppl):15s. [abstract: 5015].
30. Harding M.J., Paul J., Gillis C.R., et al. Management of malignant teratoma: does referral to a specialist unit matter?. Lancet 1993, 341(8861):1666.
31. Collette L., Sylvester R.J., Stenning S.P., et al. Impact of the treating institution on survival of patients with " poor-prognosis" metastatic nonseminoma. J Natl Cancer Inst 1999, 91(10):839-846.
32. Albers P., Siener R., Krege S., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008, 26(18):2966-2972.
33. Kollmannsberger C., Daneshmand S., So A., et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 2010, 28(4):537-542.
34. Kollmannsberger C., Tyldesley S., Moore C., et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011, 22(4):808-814.
35. Tandstad T., Smaaland R., Solberg A., et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol 2011, 29:719-725.
36. Fossa S.D., Kaye S.B., Mead G.M., et al. Filgrastim during combination chemotherapy of patients with poor- prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998, 16:716-724.
37. Houghton B.B., Grimison P.S., Toner G.C., et al. The effect of pulmonary function testing on bleomycin dosing in germ cell tumors. J Clin Oncol 2011, 29(Suppl 7):227. [abstract].